海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line treatment for R/M HNSCC (KEYNOTE-669/ECHO-304)
- Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-10-24
Authorised
- First-line chemotherapy plus pembrolizumab and olaparib for BRCA non-mutated advanced EOC
- Advanced epithelial ovarian cancer MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-10-23
Authorised
- Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
- Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma MedDRA version: 20.0 Level: HLT Classification code 10002235 Term: Anaplastic large cell lymphomas T- and null-cell types System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Croatia, Czech Republic, Hungary, Poland, Portugal, Romania, Spain, Turkey, United Kingdom
- 2013-04-15
Authorised
- A Phase 1/2 study to test how effective different doses of MEDI-551 is for treating subjects with Relapsing-Remitting Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2012-03-05
Authorised
- A 1-year study to compare long-acting insulin therapies in patients with type 2 diabetes
- Type 2 Diabetes Mellitus MedDRA version: 14.1 Level: LLT Classification code 10049746 Term: Insulin-requiring type II diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Czech Republic, Germany, Greece, Israel, Romania, Russian Federation, Spain, United States
- 2012-02-28
Authorised
- Phase 2 Dose-finding IMU-838 for Ulcerative Colitis (CALDOSE-1)
- Ulcerative Colitis MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium, Czech Republic, Germany, Netherlands, Poland, Russian Federation, Serbia, Slovakia, Spain, Ukraine, United Kingdom, United States
- 2018-02-20
Authorised
- Empagliflozin as Adjunctive to inSulin thErapy in Type 1 diabetes over 52 weeks (EASE-2)
- Type 1 diabetes mellitus br>MedDRA version: 19.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-04-02
Authorised
- MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer
- MedDRA version: 20.0 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan, United Kingdom, United States
- 2013-01-17
Authorised
- BI 1361849 (CV9202) + afatinib compared with placebo + afatinib in first-line NSCLC harbouring common EGFR mutations
- Advanced non-small cell lung cancer (adenocarcinoma) stage IV. MedDRA version: 18.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Denmark, France, Germany, Korea, Republic of, Poland, Portugal, Singapore, Spain, Taiwan, Thailand, United States
- 2015-08-17
Authorised
- Clinical Trial Testing the Safety of Four Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer
- Second Line Gastric or Gastroesophageal Junction Adenocarcinoma MedDRA version: 18.0 Level: PT Classification code 10063916 Term: Metastatic gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, France, Hungary, New Zealand, Poland, Romania, Russian Federation, Slovakia, United Kingdom, United States
- 2015-03-04
